O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham | Strategic Alliance Partners

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.

Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.

Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.

Comprehensive discussion highlighting diagnostic and molecular testing involved in the diagnosis of myelofibrosis, challenges related to early diagnosis, and consideration factors for assessing prognostic risk.

Shared insight on classification, risk factors, and important biomarkers and pathways in myelofibrosis.

Panel experts share insight regarding prognosis for patients with polycythemia vera and the associated risk for progression to myelofibrosis.

Maya Khalil, MD, discusses key clinical trial updates on the use of nivolumab and ipilimumab with or without chemotherapy in non–small cell lung cancer.

A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.

A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

Rodney Rocconi, MD, discusses the impact of the phase 3 SORAYA trial in folate receptor alpha–positive ovarian cancer.

Rodney Rocconi, MD, discusses the continued exploration of antibody-drug conjugates in patients with ovarian cancer, biomarkers and agents under investigation in the space, and the ongoing research being conducted at the O'Neal Comprehensive Cancer Center.

The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham has been awarded a five-year Cancer Center Core Support Grant of $27,477,570 from the National Cancer Institute.

TogetHER for Health is honoring the contributions of the University of Alabama at Birmingham’s Isabel Scarinci, PhD, with the first-ever Trailblazer Award for her tireless dedication to saving women’s lives both in Alabama and across the world.

Casey Weaver, MD, the Wyatt and Susan Haskell Endowed Chair for Medical Excellence in the Department of Pathology, was elected to the prestigious and esteemed National Academy of Sciences.

The potent, highly selective, next-generation PI3Kδ inhibitor parsaclisib demonstrated activity and an acceptable safety profile in patients with Bruton tyrosine kinase inhibitor-naïve relapsed/refractory mantle cell lymphoma.

This coalition of clinical research sites will partner with Genentech to advance the representation of diverse patient populations in the company’s oncology clinical trials.

Amitkumar Mehta, MD, the safety profile of liso-cel and how it is advancing the relapsed/refractory large B-cell lymphoma treatment paradigm.

Luciano J. Costa, MD, PhD, discusses the evolving treatment paradigm in newly diagnosed multiple myeloma.

Monica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.

Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.

Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years.

Susan Bal, MD, discusses key trials in the multiple myeloma space.

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, discusses the emerging role of CAR T-cell therapy in relapsed/refractory multiple myeloma, investigational products such as ide-cel, orva-cel, and JNJ-4528, and early intervention strategies to manage the toxicities associated with these products.

Luciano J. Costa, MD, PhD, discusses unmet need​s in relapsed/refractory multiple myeloma.